The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRL | -3.48% | -19.52% | -4.25% | +737% |
| S&P | +15.06% | +95.03% | +14.29% | +367% |
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Investors liked the company's Q3 update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.03B | 0.6% |
| Gross Profit | $318.16M | -5.2% |
| Gross Margin | 30.83% | -1.9% |
| Market Cap | $7.45B | -30.0% |
| Market Cap / Employee | $0.37M | 0.0% |
| Employees | 20.1K | -7.8% |
| Net Income | $52.69M | -44.1% |
| EBITDA | $251.84M | -1.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $183.22M | 2.1% |
| Accounts Receivable | $767.57M | 0.7% |
| Inventory | 279.6 | -19.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.79B | -1.8% |
| Short Term Debt | $2.93M | -8.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.89% | -6.5% |
| Return On Invested Capital | 6.23% | -1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $169.31M | 9.9% |
| Operating Free Cash Flow | $204.60M | 5.7% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 31.47 | 24.42 | 24.49 | 725.77 | 2726.88% |
| Price to Book | 2.73 | 2.50 | 2.22 | 2.33 | -20.19% |
| Price to Sales | 2.52 | 2.35 | 1.97 | 1.84 | -30.08% |
| Price to Tangible Book Value | -64.71 | -78.15 | -70.94 | -22.26 | -46.14% |
| Price to Free Cash Flow TTM | 18.25 | 18.98 | 14.04 | 12.79 | -41.86% |
| Enterprise Value to EBITDA | 54.23 | 60.56 | 48.96 | 39.91 | -23.98% |
| Free Cash Flow Yield | 5.5% | 5.3% | 7.1% | 7.8% | 72.00% |
| Return on Equity | 11.8% | 0.5% | -0.9% | -2.0% | -115.60% |
| Total Debt | $2.76B | $2.78B | $2.99B | $2.79B | -1.84% |
CRL earnings call for the period ending September 30, 2021.
CRL earnings call for the period ending June 30, 2021.
CRL earnings call for the period ending March 31, 2021.
CRL earnings call for the period ending February 17, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
